The agreement was announced on September 28, 2026, and involves AstraZeneca acquiring approximately 109,000 newly issued preferred shares in Summit Therapeutics. Once the transaction is completed, the pharmaceutical company will hold rights equivalent to approximately 12% of Summit's common shares, or around 10.6% on a fully diluted basis.
The investment is primarily linked to the development of ivonescimab, an experimental bispecific antibody that targets two mechanisms associated with cancer: PD-1 and VEGF.
Summit Therapeutics holds the development and commercialization rights to ivonescimab in major markets outside China. The drug is currently being evaluated in multiple Phase III clinical trials for different types of cancer.
As part of the agreement, Summit and AstraZeneca will also conduct clinical studies combining ivonescimab with sonesitatug vedotin (Sone-Ve), an antibody-drug conjugate (ADC) developed to target the CLDN18.2 protein, which is associated with certain types of gastrointestinal cancer.
The companies plan to launch joint studies in gastrointestinal cancers and have also announced their intention to expand the collaboration to evaluate ivonescimab in combination with other AstraZeneca oncology drugs.
Beyond the financial value of the transaction, the agreement represents another move by a global pharmaceutical company to invest in a business headquartered in Miami.
Summit Therapeutics is a biopharmaceutical company focused on oncology and treatments for other serious diseases. Its presence in Miami is part of a growing technology and business ecosystem across South Florida.
The arrival of capital and partnerships with international companies of this scale can help raise Miami's profile as a destination for businesses involved in technology, life sciences, research, and innovation.
In recent years, Miami has expanded its economic profile beyond the sectors traditionally associated with the city, such as tourism, finance, and real estate. Technology, startups, healthcare, and biotechnology are playing an increasingly important role in South Florida's business landscape.
AstraZeneca's investment in Summit Therapeutics adds to this trend, highlighting how companies with global operations and ambitions can establish a presence in Miami.
For the real estate market, the development of these sectors is also worth watching. The arrival of companies, investment capital, and specialized professionals can generate new demand for office space, housing, and services, while contributing to the economic transformation of different areas of the city.
The transaction between AstraZeneca and Summit Therapeutics remains subject to customary closing conditions. At the time of the announcement, the deal was expected to close within approximately one week.
With a $2 billion investment and a collaboration focused on developing new cancer treatments, the agreement once again puts Miami on the map for major transactions involving innovation and biotechnology.
For those following South Florida's economic development, moves like this offer another perspective on Miami's ongoing transformation and the sectors that are gaining a stronger foothold in its economy.
At Tango Realty, we see these types of investments as developments worth watching closely. A global pharmaceutical company committing $2 billion to a Miami-based business highlights how the city's economy is expanding beyond tourism, finance, and real estate. Technology, healthcare, and biotechnology are becoming increasingly significant parts of the local business landscape.
For those considering real estate investments, this matters. Industries that attract capital and specialized professionals can generate additional demand for housing, office space, and services in the areas where they establish a presence. These effects are neither immediate nor guaranteed, but they are among the factors worth considering when evaluating a rental property market over the medium and long term.
Want to learn how Miami's economic growth could translate into real estate investment opportunities? Contact us to explore the options that best align with your investment goals.
October 28, 2026
Downtown Jacksonville could soon welcome a full-service Publix supermarket, 259 rental apartments and retail space in a $140 million mixed-use development. Led by Gateway Jax, the project is part of Pearl Square, a new neighborhood spanning approximately 20 city blocks. The proposed incentive package is scheduled for a Jacksonville City Council vote on November 4.
Read moreOctober 27, 2026
South Florida’s two major indoor arenas are entering the 2026–27 season with new lounges, clubs, bars, and restaurants. The upgrades signal that demand for high-end experiences continues to grow across the region.
Read more
October 19, 2026
Holozoo Florida has leased an entire 51,000-square-foot building in Coconut Grove to open its first holographic zoo in the United States. It was Miami’s largest retail lease of the third quarter, in a market with low vacancy and record-high rents.
Read more
